Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CASR | P41180 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13948488 | 1.00 | MEN1 (0.54) | MEN1KMT2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL4204100 | 0.81 | KCNH2 (0.66) | SLC6A2SLC6A3KCNH2ADRB2ADRB1 | |
| SCHEMBL4202125 | 0.81 | KCNH2 (0.66) | SLC6A2SLC6A3KCNH2ADRB2ADRB1 | |
| SCHEMBL4196756 | 0.81 | KCNH2 (0.66) | SLC6A2SLC6A3KCNH2ADRB2ADRB1 | |
| SCHEMBL4206093 | 0.79 | KCNH2 (0.71) | MEN1KMT2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL4216135 | 0.79 | KCNH2 (0.71) | MEN1KMT2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL4209781 | 0.78 | L3MBTL1 (0.51) | MEN1KMT2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL7114181 | 0.76 | ADRB3 (0.54) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL6378942 | 0.76 | MAPT (0.43) | MEN1KMT2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL7368728 | 0.75 | L3MBTL1 (0.53) | KMT2AKCNH2ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2009-01-22 | — | — | US | disclosed |
| US-7375136-B2 | pH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1436258-A4 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | UNIV EMORY (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | disclosed |
| EP-1436258-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | Emory University (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2002072542-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | GRIN1, GRIA4, GRIA1 | MEN1 1097/4885KMT2A 259/4885SLC6A2 2149/4885 |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | GRIN1, GRIN2B, GRIN3A | MEN1 2158/4885KMT2A 338/4885SLC6A2 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.